拉米夫定对HBV-DNA及HBeAg的影响研究(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 研究拉米夫定对乙型病毒性肝炎患者机体内HBV-DNA病毒含量及HBeAg的影响。 方法 选择我院87例拉米夫定治疗的乙肝患者为实验组，并以同期56例行一般护肝治疗的乙肝患者为对照组，研究两组不同治疗阶段HBV-DNA病毒载量及HBeAg的变化特点。 结果 两组治疗前HBV-DNA平均对数值经比较，差异无统计学意义(P > 0.05)；治疗3、6个月及1年两组HBV-DNA平均对数值比较，差异均有高度统计学意义(P < 0.01)；实验组HBV-DNA、HBeAg不同时期阳性率差异有高度统计学意义(P < 0.01)，对照组HBV-DNA、HBeAg不同时期阳性率差异无统计学意义(P > 0.05)。 结论 拉米夫定对慢性乙型肝炎有很好的临床疗效。
[关键词] 慢性乙型肝炎；拉米夫定；HBV-DNA；E抗原
[中图分类号] R512.62 [文献标识码] C [文章编号] 1673-7210(2012)08(a)-0157-02
Study of influence of Lamivudine on HBV-DNA and HBeAg
SUN Aixiu ZHOU Shusheng
Department of Infection, the People's Hospital of Changyi City, Shandong Provnice, Changyi 261300, China
[Abstract] Objective To study the influence of Lamivudine on the HBV-DNA virus content and HBeAg in patients with viral B hepatitis. Methods A total of 87 patients with hepatitis B receiving Lamivudine treatment in our hospital were selected as the experiment group and 56 contemporary patients with hepatitis B receiving common live protection treatment were selected as the control group. The changes of HBV-DNA viral load and HBeAg in different treatment stages of the two groups were studied. Results The average log values of HBV-DNA before treatment between the two groups were not significantly different (P > 0.05); the average log values of HBV-DNA 3, 6 months and 1 year after treatment were all significantly different between the two groups (P < 0.01). The positive rates of HBV-DNA and HBeAg in different stages of the experiment group were significantly different (P < 0.01); the positive rates of HBV-DNA and HBeAg in different stages of the control group were not significantly different (P > 0 ......
您现在查看是摘要介绍页，详见PDF附件(2051kb)。